Pharma

Your Article Summary

See Latest Articles

Groundbreaking results in the RE-LY trial - novel oral direct thrombin inhibitor dabigatran etexilate convincingly beats warfarin - superior stroke reduction with less bleeding
Boehringer Ingelheim, 08/31/09

Boehringer Ingelheim announced data from the landmark RE–LY study – the largest atrial fibrillation outcomes trial ever conducted – presented for the first time at the European Society of Cardiology Congress and published online in the New England Journal of Medicine. Results show that dabigatran etexilate 150mg BID significantly reduces the risk of stroke and systemic embolism by 34% in patients with atrial fibrillation compared to well–controlled warfarin without increasing the risk of major bleeding. Dabigatran etexilate 110mg BID clearly demonstrated similar reductions in stroke and systemic embolism compared to well controlled warfarin while delivering an impressive 20% reduction in major bleeding rates compared to warfarin.

Today in Drug Trials...keeping you current

Receive free subspecialty "5-minute updates" via email

ARIAD Announces Full Enrollment in Phase 3 Succeed Trial Evaluating Ridaforolimus in Patients with Metastatic Sarcomas
ARIAD Pharmaceuticals, 12/18/09

Phase I trial of motexafin gadolinium and doxorubicin in the treatment of advanced malignancies
Investigational New Drugs, 12/18/09

Prognostic Factors in Idiopathic Pulmonary Fibrosis
The American Journal of the Medical Sciences, 12/17/09

 See all of Drug Trials